Systematic approach to study alternative splicing from scRNA-seq in cancer

Project Details


Alternative splicing has been shown to play important roles in cancer development. Currently, most alternative splicing studies stay on bulk RNA-seq level. Although it is estimated that 92% of human genes undergo alternative splicing, studies using bulk RNA-seq can only uncover alternative splicing for a small proportion of genes in cancer. This is due to the heterogeneous nature of cancer, in which significant splicing events specific for a cell population are averaged out over all heterogenous cells. Therefore, it is natural to resort to single cell RNA sequencing (scRNA-seq) to handle the heterogeneity in cancer. In this project, I will use a multi-omics approach to systematically study alternative splicing and its regulation from scRNA-seq of cancer.
AcronymCheng Lu AoF costs part2
Effective start/end date01/09/202331/08/2025

Collaborative partners


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.